Table 1. Basel Breast Cancer Database 1990-2009: clinicopathologic characteristics of 1,415 patients with known BMI data (16).
| Age at diagnosis: median [range] | 61 [26-95] |
| Body mass index: median (range) | 24.7 (14.3-53.3) |
| <18.5, n (%) | 38 (2.7) |
| 18.5-24.9, n (%) | 712 (50.3) |
| 25-29.9, n (%) | 425 (30.0) |
| ≥30, n (%) | 240 (17.0) |
| Tumor size: median (mm) [range] | 20 [0-220] |
| T1, n (%) | 717 (50.7) |
| T2, n (%) | 523 (37.0) |
| T3, n (%) | 80 (5.7) |
| Non-inflammatory T4, n (%) | 70 (5.0) |
| Inflammatory carcinoma (no tumor size recorded), n (%) | 23 (1.6) |
| Missing (n) | 2 |
| TNM stage (28,29), n (%) | |
| I | 527 (37.2) |
| II | 558 (39.5) |
| III | 249 (17.6) |
| IV | 81 (5.7) |
| Histological subtype, n (%) | |
| Ductal invasive | 1,097 (78.4) |
| Lobular invasive | 197 (14.1) |
| Other types | 106 (7.5) |
| Missing (n) | 15 |
| Grading, n (%) | |
| G1/G2 | 786 (57.6) |
| G3 | 578 (42.4) |
| Missing (n) | 51 |
| Hormone receptor status, n (%) | |
| ER positive/PR positive | 867 (64.1) |
| ER negative/PR negative | 239 (17.7) |
| Missing (n) | 63 |
| HER2 receptor status [2002-2009]1, n (%) (known, n=660) | |
| Positive | 113 (17.1) |
| Triple negativity [2002-2009]1, n (%) | |
| Positive | 70 (10.6) |
| St. Gallen risk score (30) [2002-2009]1,2, n (%) | |
| Low | 82 (14.2) |
| Intermediate | 400 (69.1) |
| High | 97 (16.7) |
ER, estrogen receptor; PR, progesterone receptor; 1, HER-2 has routinely been assessed for all patients since 2002 (n=665) and was available for 660 patients (46.6% of the entire study cohort); 2, only applicable for patients who had primary surgery (i.e., pTNM Classification) and known ER/PR/HER2 status, n=579.